On the road to developing new therapeutic drugs for osteoporosis and other bone degenerative diseases.
Osteoporosis is a disease that causes bones to fracture easily due to a reduction in both bone mass and quality. Aging is one of its leading causes, and it is estimated that around 200 million people are affected worldwide. Fractures of the femoral neck–the connection between the femur and the hip joint–or of vertebrae can leave a person bedridden which increases the need for care, reduces quality of life and systemic function, and increases mortality.
Bone is a living tissue that is repeatedly broken down (bone resorption) and remade (bone formation) little by little every day. If this balance collapses and bone resorption exceeds bone formation, bone density decreases and can lead to osteoporosis. Several medications are available to treat this disease, but the number of drugs that promote bone formation are far fewer compared to those that suppress bone resorption. The development of therapeutic agents that regenerate bones is highly desired.
Sirtuins are enzymes that play important roles in controlling aging, stress responses, various areas of the metabolism, and several other body functions. In mammals, there are seven types of sirtuins, SIRT1 to SIRT7. Although SIRT7 has been reported to be involved in cancer and lipid metabolism, its role in bone tissue and bone aging was unknown.
1. The effect of SIRT7 on bone formation
Recent experiments performed by a research group led by scientists from Kumamoto University, Japan showed that mice lacking the SIRT7 gene had reduced bone mass. A bone morphometry analysis showed that bone formation and the number of osteoblasts (bone-building cells) had been reduced. Furthermore, the researchers obtained similar results using osteoblast-specific SIRT7 deficient mice, thereby showing that (osteoblast-specific) SIRT7 is important for bone formation.
2. Expression of sirtuins in bone tissue of old mice
Reduced bone formation is common in people with osteoporosis, and the mechanism for this reduction is not well known. To clarify the mechanism, the researchers compared sirtuin (SIRT1, 6, and 7) expression in the skeletal tissue of young and old mice, and found that SIRT7 decreased with age. They then considered that this decrease in SIRT7 in the older specimens may be associated with decreased osteogenesis, and may even be a cause of osteoporosis.
3. The effect of SIRT7 on osteoblast differentiation
When the researchers cultured osteoblasts (in vitro) with decreased SIRT7 expression in their next experiment, the formation of a bone-like mass (calcified nodule) was markedly suppressed compared to cultures of normal osteoblasts. Additionally, the expression of genes indicating osteoblast differentiation was also decreased, thereby revealing that SIRT7 controls the differentiation of osteoblasts.
4. Transcriptional activation of SP7/Osterix by SIRT7
To clarify the mechanism by which osteoblastic SIRT7 positively regulates the differentiation of osteoblasts, researchers investigated the transcription activity of the gene expression regulatory factor essential for osteoblast differentiation. They found that the transcription activity of SP7 (also known as Osterix), a protein known to induce differentiation of pre-osteoblasts into mature osteoblasts and osteocytes, was markedly decreased in osteoblasts that lacked the SIRT7 gene.
They also realized that to get high transcription activation of SP7/Osterix, it is important for SIRT7 to deacylate the 368th lysine residue of the SP7/Osterix protein. In other words, SIRT7 enhances the transcriptional activity of SP7/Osterix by chemically modifying it (deacylating the 368th lysine residue). Furthermore, the researchers were able to recover osteoblast functionality in the calcified nodule formation by introducing a mutant SP7/Osterix, which deacylated the 368th lysine of SP7/Osterix, into the osteoblasts that had reduced SIRT7 expression.
The research group is confident that their results show a new mechanism for SIRT7 as a deacylating enzyme important for transcriptional activation of the gene expression regulator SP7/Osterix and is essential for osteoblast differentiation.
“In situations where SIRT7 does not work sufficiently, such as in an older individual, osteoblast formation is impaired due to low SP7/Osterix transcriptional activity. We believe that this decreased osteogenesis is associated with osteoporosis,” said study leader Dr. Tatsuya Yoshizawa of Kumamoto University. “Our results, show that the regulatory pathway of SIRT7 – SP7 / Osterix is a promising target for new therapeutic agents to treat decreased osteogenesis and osteoporosis.”
The Latest on: Bone degenerative diseases
via Google News
The Latest on: Bone degenerative diseases
- The Middle East & Africa cartilage degeneration market is expected to reach US$ 511.76 million by 2027 from US$ 426.91 million in 2019on November 26, 2020 at 4:28 am
Reportlinker.com announces the release of the report "Middle East & Africa Cartilage Degeneration Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Procedure Type, Application, and ...
- Volar and Dorsal Blood Supply to the Lunate: A Cadaveric Studyon November 25, 2020 at 2:33 pm
Although various studies have proposed vascular and mechanical factors, the etiology of Kienböck disease is unknown. Kienböck theorized that lunatomalacia resulted from traumatic disruption of blood ...
- Exposure to Outer Space May Accelerate Aging, New Evidence Suggestson November 25, 2020 at 1:00 pm
A fascinating batch of new research papers highlight the various health risks associated with long-duration space missions, including troublesome observations having to do with the aging process and ...
- Orthopedic Implants Market Is Expected to Generate Global Revenue Worth US$ 79.5 billion by 2030on November 25, 2020 at 9:48 am
The global orthopedic implants market size was estimated to be US$ 47 billion in 2019 and expected to reach US$ 79.5 billion by 2030 at a CAGR of 5% through 2030. Orthopedic implants are used to ...
- Exposure to Outer Space May Accelerate Ageing, New Evidence Suggestson November 25, 2020 at 8:26 am
Without gravity perpetually pulling us downward, and without a protective atmosphere to shield us from the Sun’s deadly rays, we become exposed to a plethora of health risks — things like loss of bone ...
- Finding a Fix for Faulty Geneson November 25, 2020 at 7:57 am
In August 2017, Israel’s T cells were collected from his blood and their genes were altered to recognize and target CD19, a protein on the surface of lymphoma cells. The engineered T cells were ...
- The South & Central America cartilage degeneration market is expected to reach US$ 1,195.57 million by 2027 from US$ 959.32 million in 2019on November 24, 2020 at 7:30 am
The South & Central America cartilage degeneration market is expected to reach US$ 1,195.57 million by 2027 from US$ 959.32 million in ...
- Turnout: Today’s and Forecast top business news about Collagen Peptides Marketon November 24, 2020 at 1:43 am
As collagen peptides are attaining admiration, there are so many questions that might swirl in your head: What exactly are collagen peptides? What are they used for? And, even more importantly, why ...
- Week In Review: BeiGene Plans $2.5 Billion IPO On Shanghai Star Exchangeon November 22, 2020 at 1:34 pm
BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (SREs) in ...
via Bing News